Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study
Multicenter, double-blind trial shows improved hair regrowth with topical GT20029 in male patients, suggesting therapeutic potential in androgenetic alopecia.
Key Points
Topical GT20029 demonstrated significant efficacy in hair regrowth with good tolerability, enhancing treatment options.
A double-blind, placebo-controlled phase 2 study evaluated the effects of topical GT20029 in male patients.
The multicenter design allows for diverse patient recruitment, increasing generalizability of results.
Further studies are warranted to confirm its therapeutic potential in androgenetic alopecia.